Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2024, Vol. 29 ›› Issue (4): 475-480.doi: 10.12092/j.issn.1009-2501.2024.04.017

Previous Articles    

Progress in the potential therapeutic mechanism of mesenchymal stem cell-derived exosomes for liver fibrosis

ZHAO Tingting1, LI Junfeng1,2, ZHANG Liting2,1,3   

  1. 1 First Clinical College of Lanzhou University, 2 Department of Hepatology, The First Hospital of Lanzhou University, 3 Portal Hypertension Research Institute, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China
  • Received:2023-10-13 Revised:2023-11-30 Online:2024-04-26 Published:2024-03-25

Abstract:

Liver fibrosis is pathological in most chronic liver diseases. Exosomes secreted by mesenchymal stem cells (MSCs) can regulate liver fibrosis through mechanisms such as inhibition of inflammatory response and proliferation of activated hepatic stellate cells, regulation of immune cells and metabolism. Therefore, MSC-derived exosomes can be used as a cell-free therapy for chronic liver disease, expanding new ideas for the treatment of chronic liver disease. Recent researches on MSC-derived exosomes in the treatment of liver fibrosis are reviewed in this article.

Key words: mesenchymal stem cells, exosomes, liver fibrosis, therapeutics, mechanism

CLC Number: